Use of phosphodiesterase 4 inhibitor in patients with psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints, spine, and entheses, which is associated with psoriasis. The pathological process is localized mainly in the tissues of the locomotor system and leads to the development of erosive arthritis, intra-articular osteolysis, and s...
Saved in:
Main Authors: | V. I. Mazurov, E. A. Trofimov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2017-04-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/759 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The place of a phosphodiesterase 4 inhibitor in the treatment strategy for psoriatic arthritis
by: V. I. Mazurov, et al.
Published: (2018-04-01) -
Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01) -
New opportunities in the treatment of psoriasis and psoriatic arthritis
by: A. A. Kubanov, et al.
Published: (2019-01-01) -
The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
by: E. Yu. Loginova, et al.
Published: (2019-07-01) -
THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2016-12-01)